Bipolar Disorder Treatment Market - By Disorders Type (Bipolar I, Bipolar II), By Drug Class (Anticonvulsants, Antianxiety, Mood Stabilizers, Antipsychotic, Antidepressant, Others), By Mechanism of Action (Selective Serotonin Reuptake Inhibitor, Serotonin Norepinephrine Reuptake Inhibitors, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors, Benzodiazepines, Beta Blockers), By End User (Hospitals, Homecare, Specialty Clinics, Others), - Global Opportunity Analysis and Industry Foreca

Bipolar Disorder Treatment Market held USD 5906.5 million in 2020 and is to grow with a CAGR of 2.7% from 2020-2030. Bipolar disease is a type of mental infection, also called bipolar depression. It is characterized by mood swings. Episodes of mood are of different types: manic and depressive episodes. The changes inside a person's mental state result in sudden excessive or low moods. An individual with bipolar disorder may be happy, joyful, and energized at a specific second, and may also be sad, hopeless, and gradual at the next second. Because of these different moods or temper poles, this intellectual disease is named as bipolar sickness. Miles have found that certain genes are accountable for the development of bipolar ailment through many studies activities.

Market Dynamics and Factors:

The main drivers for market growth are increased awareness of the diagnosis and treatment of bipolar disease and unsatisfied needs when treating the problem. Increased social tolerance of mental illness helps individuals to seek care. In addition, increasing technological progress in the identification of genetic disorders and increasing treatment options for genetic disorders are key drivers of the growth of the market. Government initiatives, like the launching of the National Institute of Mental Health (NIMH) Bipolar Disorder Phenome Database, provide comprehensive information on the signs and symptoms of the disease. This factor contributed additionally to the growth of bipolar disorder treatment market. Factors such as strict regulatory laws and frameworks, side effects of anticonvulsants, and low count of approved anticonvulsants might restrain the growth of bipolar disorder treatment market.

Market Segmentation:

Based on the disorder type, the bipolar disorder treatment market size is segmented into Bipolar I and Bipolar II. By drug class, the bipolar disorder treatment market trends vary into mood stabilizers, anticonvulsants, antianxiety, antipsychotic, antidepressant, others. On the basis of mechanism, the market is segregated into benzodiazepines, selective serotonin reuptake inhibitor, tricyclic antidepressants, monoamine oxidase inhibitors, serotonin norepinephrine reuptake inhibitors, beta blockers. On the basis of end-user, the market is segmented into the hospitals, homecare, specialty clinics, others. Geographical breakdown and analysis of each of the aforementioned segments includes regions comprising North America, Europe, Asia-Pacific, and ROW.

Geographic Analysis:

North America dominates the bipolar disorder treatment market share with the large demand owing to rising bipolar cases in this region. The region is also a hub of advanced healthcare infrastructure which has led to advanced knowledge and easy accessibility to treatment alternatives. Asia Pacific is also growing at a fast pace and expected to dominate in the future owing to rising economy and enhancement in knowledge about the syndromes in the Asian developing economies. Growing awareness and concern regarding mental sickness is further anticipated to drive market growth in this region.

Competitive Scenario:

Global bipolar disorder treatment market, is highly competitive, consists of a few major players. In terms of market share, few of the major players constitute large share of market. Key companies are also expanding their manufacturing facilities to cater to growing demand for this drug globally. Key players enhancing the global Bipolar Disorder Treatment market size include AbbVie Inc, Allergan, Novartis AG, Mallinckrodt plc, Johnson & Johnson Services, Inc, Sun Pharmaceutical Industries Ltd., Avet Pharmaceuticals Inc., Zydus Cadila, Endo Pharmaceuticals plc, Mylan N.V., Teva Pharmaceutical Industries Ltd, Mayne Pharma Group Limited, Amneal Pharmaceutical Inc.

Bipolar Disorder Treatment Market Report Scope